Navigation Links
Amylin Pharmaceuticals Reports Third Quarter Financial Results
Date:10/20/2009

2008. Revenues under collaborative agreements were $44.6 million for the nine months ended September 30, 2009, compared to $57.2 million for the same period in 2008. The decrease reflects lower cost-sharing payments from Lilly for development expenses for BYETTA and exenatide once weekly.

Selling, general and administrative expenses decreased to $259.7 million for the nine months ended September 30, 2009, from $309.0 million for the same period in 2008. The decrease primarily reflects lower sales force and business infrastructure expenses driven by the Company's reduced cost structure.

Research and development expenses decreased to $176.3 million for the nine months ended September 30, 2009, from $226.1 million for the same period in 2008. The decrease primarily reflects decreased development expenses for exenatide once weekly and the Company's obesity programs following recently completed clinical trials and efficiencies driven by the Company's reduced cost structure. Research and development expenses for the nine months ended September 30, 2008 included an $8.0 million license payment for drug delivery technology. Non-GAAP research and development expenses net of cost-sharing payments decreased to $134.9 million for the quarter ended September 30, 2009 compared to $172.1 million for the same period in 2008.

Collaborative profit sharing was $227.5 million for the nine months ended September 30, 2009, compared to $229.4 million for the same period in 2008.

Non-GAAP operating loss was $41.7 million for the nine months ended September 30, 2009, a 64% improvement over the $117.0 million loss for the same period in 2008. Net loss was $136.0 million, or $0.97 per share for the nine months ended September 30, 2009, compared to $216.7 million, or $1.58 per share, for the same period in 2008. Net loss for the nine months ended September 30, 2008 included a loss on impairment of investments of $14.9 million, or $0.11 p
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... , June 3, 2015 MEDTEC China South 2015 came ... of MEDTEC China 2015, MEDTEC China South has been recognized ... out as a key event for the medical device manufacturing ... years of challenges, this year marks the successful return of the ... after the event first debuted there in 2005. ...
(Date:6/3/2015)...   Health Data Consortium (HDC) , a public-private partnership whose mission ... to improve health and healthcare, today announced Niall Brennan ... Office of Enterprise Data and Analytics at the Centers ... of this year,s Health Data Liberators Award ... ways to help improve the quality and value of ...
(Date:6/3/2015)...  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a ... expertise in opioid antagonists, announced today that Adapt ... overdose with intranasal naloxone, has commenced a rolling ... the United States Food and Drug Administration (FDA) ... drug intended to treat opioid overdose.  A rolling ...
Breaking Medicine Technology:MEDTEC Successfully Returns to Southern China 2MEDTEC Successfully Returns to Southern China 3CMS Chief Data Officer and Health Data Advocate Niall Brennan Receives Third Annual Health Data Liberators Award 2CMS Chief Data Officer and Health Data Advocate Niall Brennan Receives Third Annual Health Data Liberators Award 3CMS Chief Data Officer and Health Data Advocate Niall Brennan Receives Third Annual Health Data Liberators Award 4Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 2Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 3
... 18, 2011 Reportlinker.com announces that a ... its catalogue: China ... http://www.reportlinker.com/p0590608/China-Contract-Research-Organization-CRO-Industry-Report-2010-2011.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Disc ... high R&D costs of new drugs worldwide, ...
... from Texas has invented a miraculous new medical laser ... inventions and scientific advancements in modern history. The miraculous ... organs to kill harmful germs and bacteria during surgical ... currently contribute to the estimated 100,000 annual deaths attributed ...
Cached Medicine Technology:China Contract Research Organization (CRO) Industry Report, 2010-2011 2China Contract Research Organization (CRO) Industry Report, 2010-2011 3China Contract Research Organization (CRO) Industry Report, 2010-2011 4China Contract Research Organization (CRO) Industry Report, 2010-2011 5New Life Saving Medical Invention Announced by Perry Felix 2
(Date:6/3/2015)... June 03, 2015 “ Harmony ” was ... takes a look at the latest and coolest applications on ... host of AppWatch and technology expert, conducted the app review ... that wants to improve some aspect of their life. , ... only for people with difficulties in their life. However, hypnotherapy ...
(Date:6/3/2015)... 03, 2015 Follow us on ... has revolutionized disease treatment on account of their better ... diseases, such as rheumatoid arthritis. The industry is expected ... traditional small molecule drugs to biopharmaceuticals over the coming ... cell and gene therapies, and recombinant proteins has attracted ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 On the heels ... $13 billion industry by 2020 ( click here to ... computer scientists believe Baltimore has the talent to ... in which genetic code and other biological data are collected ... disease. “Baltimore contains all the elements of a perfect ...
(Date:6/3/2015)... 03, 2015 Dr. Steven Reisman, a nationally ... Center ( http://www.newyorkcardiac.com ) located in NYC, announced today the ... his practice. In most cases, depending on the level of ... they call, they will be seen by a cardiologist that ... a cardiologist is to ensure that people who have an ...
(Date:6/3/2015)... WA (PRWEB) June 03, 2015 ... insurance exchange technology, has announced that CEO Jonathan Rickert ... Institute 2015 on June 4, 2015. The session ... digital technologies are disrupting traditional business models in health ... business value. , WHAT: Digital Transformation and the ...
Breaking Medicine News(10 mins):Health News:An Application to Enjoy Hypnotherapy Sessions at Home was featured on NewsWatch Television 2Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 4Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 2Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 3Health News:NYC Cardiologist, Dr. Steven Reisman, Announces Same Day and Evening Appointments 2Health News:Array Health’s CEO to Present at America’s Health Insurance Plans Institute 2015 2
... which diet would work best for you, study suggests , WEDNESDAY, ... cut carbs or fats to lose weight? A DNA test using ... you, new research suggests. , Researchers from Stanford University used data ... women were assigned to one of four popular diets for a ...
... , ... ... ... ...
... ... ... ... ...
... Ill. -- A daily dose of vitamin D may just ... according to researchers at Loyola University Chicago Marcella Niehoff School ... months when days are short and more time is spent ... despite the nutrient,s widely reported health benefits," said Sue Penckofer, ...
... youth means trouble by mid-40s, despite activity levels, study finds , ... in their 20s and 30s are more apt to develop heart ... people who spent less time in front of the screen, a ... the worse news is that you can,t exercise the risk away. ...
... , ... ... ... ...
Cached Medicine News:Health News:A Cheek Swab to Choose Your Diet Plan? 2Health News:A Cheek Swab to Choose Your Diet Plan? 3Health News:Saks 5th Ave, By Kilian, Versace, Barefoot Wine & Bubbly, GL Homes, Bluefly and NUVO Support Women On The Move's 'Unveil Your Pink' Event! 2Health News:Saks 5th Ave, By Kilian, Versace, Barefoot Wine & Bubbly, GL Homes, Bluefly and NUVO Support Women On The Move's 'Unveil Your Pink' Event! 3Health News:Saks 5th Ave, By Kilian, Versace, Barefoot Wine & Bubbly, GL Homes, Bluefly and NUVO Support Women On The Move's 'Unveil Your Pink' Event! 4Health News:Saks 5th Ave, By Kilian, Versace, Barefoot Wine & Bubbly, GL Homes, Bluefly and NUVO Support Women On The Move's 'Unveil Your Pink' Event! 5Health News:Saks 5th Ave, By Kilian, Versace, Barefoot Wine & Bubbly, GL Homes, Bluefly and NUVO Support Women On The Move's 'Unveil Your Pink' Event! 6Health News:Saks 5th Ave, By Kilian, Versace, Barefoot Wine & Bubbly, GL Homes, Bluefly and NUVO Support Women On The Move's 'Unveil Your Pink' Event! 7Health News:Aspen Dental Announces Results of Its 'An Hour for Haiti' Employee Donation Program 2Health News:Aspen Dental Announces Results of Its 'An Hour for Haiti' Employee Donation Program 3Health News:Vitamin D lifts mood during cold weather months 2Health News:You Can't Exercise Away TV's Toll on the Heart 2Health News:You Can't Exercise Away TV's Toll on the Heart 3Health News:Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock 2Health News:Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock 3
... The VERSAPORT™ RT cannulas are all able ... systems packaged for use with the RT ... are all able to be used with ... with the RT system. The trocars include: ...
... trocar has a sharp linear blade and a ... VERSAPORT™ PLUS V2 trocar is available in 5 ... 5 mm-12 mm long sizes with a radiolucent ... has a sharp linear blade and a spring-loaded ...
... Auto Suture™ SPRING-GRIP™ single use nonconductive anchoring ... mm, 11 mm and 12 mm sizes ... and 5 mm, 5 mm-10 mm, 5 ... mm-15 mm sizes for use with the ...
... Access ...unlike any trocar system you've ever ... actually four systems in one designed ... adaptive to all of your needs., ... or dilating tip styles, OnePort™ can effectively ...
Medicine Products: